Iambic Therapeutics

Rounds and research, on one timeline

1. 2026-10-14IPO
   Round

   $150M

   For: finish IAM1363's Phase 1 and start Phase 2 and 3 trials; take IAM217 and IAM-C1 through Phase 1 dose escalation; the AI platform

   Toward the clinicModels and platform

   9,375,000 shares at $16, all sold by Iambic, $150.0M gross; underwriters hold a 30-day option on 1,406,250 more. The offering was due to close on 16 October 2026. Use of proceeds from the S-1/A of 8 October (https://www.sec.gov/Archives/edgar/data/0001997038/000119312526417416/iam-20261008.htm), which also says ARK and Duquesne Family Office indicated interest in up to $60M of shares; the pricing release does not say whether they bought, so neither is recorded as an investor.

   No investor named in the source.

   Advisers: J.P. Morgan (joint book-running manager); Jefferies (joint book-running manager); BofA Securities (joint book-running manager); Citigroup (joint book-running manager)

   By this date the record held 1 research entry, highest level 2

   Announced by the company · iambic.ai ↗On the timeline →

2. 2026-09-21
   Research

   Level 2 · Computed

   Iambic describes Enchant v3, a 41-billion-parameter in-house model that predicts drug properties from 16 kinds of data, and says accuracy has kept rising with scale

   Iambic's case to investors, and part of what its IPO pays for, is that one model trained on many kinds of drug data predicts better than many narrow ones and keeps improving with size. The report says that has held across three versions, and names two programmes Enchant helped optimise, IAM-C1 and IAM217.

   Timeline entry →iambic.ai ↗

3. 2025-11-10Round (unnamed)
   Round

   over $100 million

   For: take KIF18A and CDK2/4 programs into the clinic

   Toward the clinic

   No lead or series named.

   Abingworth ✓Regeneron VenturesQatar Investment AuthorityMubadalaSequoia ✓ARKAlexandria Venture InvestmentsAlumni VenturesAscenta ✓Catalio ✓Everbright BiofundFreeflow VenturesIllumina Ventures ✓Pegasus Tech VenturesTao Capital PartnersTerra Magnum Capital PartnersWilson Sonsini Goodrich & Rosati

   The investor's own page says · Sequoia: 2021

   Announced by the company · iambic.ai ↗

4. 2024-06-18Series B extension
   Round

   $50M

   For: advance IAM1363 and CDK2/4 programs

   Toward the clinic

   Co-lead · Mubadala CapitalCo-lead · Exor VenturesQatar Investment AuthorityAbingworth ✓Illumina Ventures ✓Coatue ✓Nexus Venture Partners ✓Tao Capital Partners

   On the deal: Ayman AlAbdallah (Partner, Mubadala Capital)

   Announced by the company · iambic.ai ↗

5. 2023-10-03Series B
   Round

   $100M

   For: take AI-discovered candidates into the clinic

   Toward the clinic

   Co-lead · Ascenta Capital ✓Co-lead · Abingworth ✓NVIDIA ✓Illumina Ventures ✓Coatue ✓OrbiMed ✓Sequoia Capital ✓Catalio ✓Gradiant CorporationShandaBill RastetterNexus Venture Partners ✓Freeflow VenturesTao Capital Partners

   On the deal: Bill Rastetter (Independent director, investing personally, joins the board); Evan Rachlin (Co-founder and Managing Partner, Ascenta Capital, joins the board); Kurt von Emster (Managing Partner and Head of Life Sciences, Abingworth, joins the board); Ron Mazumder (Partner, Illumina Ventures); Rory Kelleher (Director of Healthcare and Life Sciences, NVIDIA)

   Announced by the company · iambic.ai ↗

6. 2021-07-14Series A
   Round

   $53M

   For: build the platform and San Diego lab

   Models and platformWet lab

   Raised under the company's former name, Entos.

   Co-lead · Coatue ✓Co-lead · Catalio Capital Management ✓OrbiMed ✓Sequoia Capital ✓Nexus Venture Partners ✓Freeflow Ventures

   On the deal: Aaron Weiner (Managing Director and Head of Healthcare, Coatue, joins the board); Naren Gupta (Co-founder and Managing Director, Nexus Venture Partners, joins the board); R. Jacob Vogelstein (Co-founder and Managing Partner, Catalio Capital Management, joins the board)

   Announced by the company · biospace.com ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →